BeiGene: cross-border access for the specialty portfolio
Quick orientation
BeiGene, Ltd. (recently rebranded to BeOne Medicines) is a global oncology company with operating roots in China and a US headquarters in San Mateo, California. BeiGene operates a substantial US clinical and commercial organisation and trades on NASDAQ as BGNE, on the Hong Kong Stock Exchange, and on the Shanghai Stock Exchange. FDA approval scale spans multiple oncology products including the next-generation BTK inhibitor Brukinsa and the PD-1 inhibitor Tevimbra. The company's hematology franchise has competed directly with Imbruvica (ibrutinib) in the BTK inhibitor space and has accumulated multiple FDA approvals across chronic lymphocytic leukemia, mantle cell lymphoma, Waldenström macroglobulinemia, marginal zone lymphoma, and follicular lymphoma.
BeiGene portfolio in cross-border NPP scope
Brukinsa (zanubrutinib) is an FDA-approved second-generation Bruton's tyrosine kinase (BTK) inhibitor for chronic lymphocytic leukemia or small lymphocytic lymphoma (FDA approval January 2023), mantle cell lymphoma (initial accelerated approval November 2019, post-marketing requirements completed), Waldenström macroglobulinemia, marginal zone lymphoma, and relapsed or refractory follicular lymphoma in combination with obinutuzumab. Oral dosing, once or twice daily. US list pricing is approximately US$15,500 per month. Brukinsa demonstrated superiority over ibrutinib in the head-to-head ALPINE trial in relapsed/refractory CLL on progression-free survival.
Tevimbra (tislelizumab-jsgr) is an FDA-approved PD-1 immune checkpoint inhibitor for adult patients with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy (FDA approval March 2024) and for first-line gastric or gastroesophageal junction adenocarcinoma in combination with chemotherapy (FDA approval December 2024). Intravenous administration every three weeks. The product is engineered with minimal Fc-gamma receptor binding to potentially reduce immune-related adverse event mechanisms.
BeiGene's pipeline includes BCL2 inhibitor sonrotoclax (in development for CLL and other hematologic malignancies), BTK-CDAC degrader BGB-16673, and additional oncology candidates. These are investigational and not in NPP scope. The Novartis partnership on Tevimbra in non-US markets was terminated in 2023; BeiGene now holds global commercialisation rights for Tevimbra outside the US for additional indications.
Why patients route through cross-border NPP
Brukinsa is the highest-volume cross-border NPP demand driver in the BeiGene portfolio. The CLL and lymphoma patient populations are sizable, and oncologists in major centers globally are increasingly selecting next-generation BTK inhibitors over ibrutinib based on tolerability and the ALPINE trial efficacy signal. Outside the United States, Brukinsa is approved in the European Union, the UK, China, and a growing list of markets, but country-by-country reimbursement and stocking remain uneven across the GCC, India, Turkey, and parts of MENA and Southeast Asia.
Tevimbra serves a distinct cross-border profile. Esophageal squamous cell carcinoma is more common in Asian populations than in Western populations, and access to second-line PD-1 inhibitors after platinum-based chemotherapy is variable globally. Tevimbra's gastric cancer indication is also broadly relevant in Asian patient populations where gastric cancer incidence is high. Patient profile is typically: confirmed pathology with PD-L1 staining where required; documentation of prior lines of therapy; preserved performance status; and the local site has infusion and immune-related adverse event management capability.
Common cross-border destinations
The highest-frequency NPP destinations for BeiGene products from US-approved inventory are India, the United Arab Emirates, Saudi Arabia, Turkey, and Egypt. Hematology centers for Brukinsa and GI oncology centers for Tevimbra in Mumbai, Bangalore, Delhi, Hyderabad, Dubai, Riyadh, Istanbul, and Cairo drive most inbound referrals.
Manufacturer engagement posture
Reserve Meds coordinates BeiGene-sourced US commercial product through DSCSA-compliant US specialty distributors. We are not affiliated with BeiGene. Our role is patient-facing coordination on behalf of named individual patients with a verified oncology prescription. For BeiGene medical affairs or US commercial teams interested in cross-border NPP pathways, our BD contact is [email protected].
What Reserve Meds provides
For each BeiGene product request, Reserve Meds coordinates: prescription verification with the treating hematologist-oncologist or solid-tumor oncologist; biomarker and indication documentation review where required (CLL/lymphoma diagnosis confirmation; PD-L1 staining for some Tevimbra protocols); DSCSA serialized chain-of-custody from BeiGene through licensed US wholesalers to the named patient; cold-chain shipping (2 to 8 degrees C) for Tevimbra with temperature data-loggers; ambient shipping for oral Brukinsa; destination-country regulatory documentation for Ministry of Health named-patient approvals and customs clearance; and a dedicated coordinator from prescription to delivery.
Clinical governance and prescription review
Every prescription for a product on this page is reviewed by a US-licensed pharmacist before dispensing. Reserve Meds does not substitute generic equivalents for branded specialty products without an explicit prescriber instruction, and we do not dispense any product whose chain-of-custody we cannot serialize back to the FDA-authorised manufacturer or its licensed wholesale partner. Our clinical review confirms indication-on-label appropriateness based on the documentation submitted by the treating physician, identifies any standard drug-drug interaction or contraindication concerns, and confirms that the requested dose, dosing schedule, and dosage form match the prescription. Where the prescription is unclear or where the indication on the prescription is off-label, our pharmacist contacts the prescriber directly. We do not provide medical advice to patients beyond drug-information counseling at dispensing.
Supply chain integrity
Supply integrity is the foundation of Reserve Meds operations. Every shipment carries a serialized DSCSA pedigree document confirming the chain of ownership from the FDA-registered manufacturer or its authorised distributor through a licensed US wholesale distributor to Reserve Meds and onward to the named patient. We do not source through parallel-import channels, third-country re-import, or unverified online wholesale markets. Cold-chain shipments are packed in qualified shippers with temperature data-loggers reading and logging temperature throughout the journey; data-logger reads are reviewed on arrival, and any out-of-specification excursion triggers our quality-hold protocol. For frozen products such as gene therapies and certain antibody-drug conjugates, we use validated frozen-shipper systems with dry-ice replenishment as required.
Destination-country regulatory pathways
Cross-border named patient access operates under jurisdiction-specific regulatory frameworks. In the United Arab Emirates, the Ministry of Health and Prevention (MOHAP) and Dubai Health Authority operate import-permit pathways for unregistered or restricted medicines on a named-patient basis. Saudi Arabia, Qatar, Kuwait, Bahrain, and Oman each operate analogous Ministry of Health named-patient frameworks with country-specific documentation requirements. India operates a personal-import pathway under the Drugs and Cosmetics Rules for quantities consistent with personal therapeutic use, typically up to three months supply per shipment. Turkey, Egypt, Jordan, Lebanon, and Morocco each operate distinct named-patient or import-permit pathways. Reserve Meds maintains current regulatory intelligence for each of these jurisdictions and prepares the documentation package required for each shipment.
What to expect through the coordination process
Patients beginning a request receive an initial coordinator contact within one business day of submission. The coordinator reviews the prescription, identifies the documentation required for the destination country, and provides an indicative cost range. Once required documents are uploaded - prescription, prescriber license verification, patient identification, and any indication-specific documentation such as genetic test results or biomarker reports - we issue a firm quote inclusive of product cost, packaging, shipping, regulatory documentation, and our coordination fee. Patients confirm acceptance of the firm quote before any sourcing or shipping is initiated, and Reserve Meds does not collect any deposit at intake. Once the firm quote is accepted and payment is received, the coordinator initiates sourcing through our licensed wholesale partners and prepares the destination-country regulatory package. Typical end-to-end timing from accepted quote to delivery is two to four weeks for ambient-shipped products and three to five weeks for cold-chain shipments, with variability driven by destination-country customs and regulatory turnaround times.
Not affiliated with the manufacturer
Reserve Meds is an independent operator of named patient program coordination. We are not a subsidiary, affiliate, authorised distributor, or licensed representative of any pharmaceutical manufacturer, and no statement on this page should be read as a partnership, endorsement, or representation by the named manufacturer. Trade names and product references on this page are used for informational purposes to identify the FDA-approved products that Reserve Meds coordinates through US specialty wholesale channels on behalf of named individual patients.
Privacy and data handling
Patient data submitted to Reserve Meds is handled under our HIPAA-aligned privacy policy and our destination-country data protection commitments. We minimise data collection to what is necessary for prescription verification, regulatory documentation, and shipping logistics. Patient identifiable information is shared with US wholesalers, destination-country regulatory authorities, and shipping carriers only as required to complete the coordination, and is not used for any marketing purpose.
Next step for patients
Patients with a treating-physician prescription for a BeiGene product can begin a request now. Start a request ›
Next step for BeiGene teams
BeiGene medical affairs or commercial teams interested in cross-border NPP coordination for non-US territories can reach our BD team at [email protected].
Reserved for you.